Paul Bunn
Director/Board Member at VERASTEM, INC.
Net worth: - $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dan Paterson | M | 63 | 13 years | |
Daniel Calkins | M | 37 | 6 years | |
Michael Kauffman | M | 60 | 12 years | |
Richard Duke | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | - |
Brian Stuglik | M | 64 | 7 years | |
John M. Stewart | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
Michelle Robertson | F | 57 | 3 years | |
Lajos Gera | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
Daniel D. Chan | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
Eric Rowinsky | M | 67 | 7 years | |
Anil Kapur | M | 54 | 2 years | |
Robert Gagnon | M | 49 | 6 years | |
Donald Bellgrau | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
Cathy Carew | F | - | - | |
John Johnson | M | 66 | 4 years | |
Eduardo da Cruz | M | - |
The University of Colorado School of Medicine
| - |
Zhi Lin Song | M | 55 |
The University of Colorado School of Medicine
| 10 years |
Gerald M. Haase | M | - |
The University of Colorado School of Medicine
| - |
Karin Tollefson | M | 57 | 1 years | |
David Mitchell | M | 67 | 1 years | |
Philip S. Mehler | M | - |
The University of Colorado School of Medicine
| - |
Malik Kahook | M | - |
The University of Colorado School of Medicine
| - |
David Ross Camidge | M | - |
The University of Colorado School of Medicine
| 17 years |
Ovidio B. Bermudez | M | - |
The University of Colorado School of Medicine
| - |
Jaime Modiano | M | - |
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | 18 years |
Jonathan Pachter | M | 66 | 13 years | |
Hagop Youssoufian | M | 67 | 7 years | |
Charles A. Dinarello | M | 81 |
The University of Colorado School of Medicine
| 28 years |
Michael Crowther | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gina Consylman | F | 52 | 3 years | |
Timothy Barberich | M | 76 | 8 years | |
Lesley Solomon | F | 52 | 2 years | |
Lisa Buffington | F | - | 4 years | |
Ajay Munshi | M | - | - | |
Louis J. Denis | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 35 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Bunn
- Personal Network